PROVECTUS BIOPHARMACEUTICALS, INC.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT): 3 pipeline candidates · ~3 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
2.5 months
D/E -1.09 · 0% dilution
Lead: Phase 3
3 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for PROVECTUS BIOPHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$25.9M
Cash
$224K
Quarterly Burn
$358K
Runway
2.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in PROVECTUS BIOPHARMACEUTICALS, INC.'s pipeline?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROVECTUS BIOPHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PROVECTUS BIOPHARMACEUTICALS, INC. has approximately 2.5 months of cash runway.
What is PROVECTUS BIOPHARMACEUTICALS, INC.'s market capitalization?
PROVECTUS BIOPHARMACEUTICALS, INC.'s market capitalization is approximately $25.9M.
Who is the CEO of PROVECTUS BIOPHARMACEUTICALS, INC.?
Mr. Edward V. Pershing CPA is the chief executive officer of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
Get the full picture on PROVECTUS BIOPHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.